Parse Biosciences Launches Single Cell Immune Profiling Products
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line. The new BCR solution and updates to the existing TCR product line expand Parse’s single cell portfolio and will enable researchers to study the immune repertoire at unprecedented resolution and scale.
Single Cell Immune Profiling Products allows researchers to capture B cell receptor (BCR) sequences together with gene expression from the same cells. While existing tools struggle to capture the immense diversity of the BCR repertoire, Evercode BCR offers a breakthrough by measuring paired BCR sequences (both heavy and light chains) in up to one million cells in a single experiment. This scalable approach enables assignment of BCR clonotypes to various B-cell subtypes and activation states, providing unprecedented resolution and unleashing new capabilities in antibody discovery.
Parse has also expanded its Evercode TCR product line to enable detection of both mouse and human TCRs and dramatically improved performance. These updates provide improved sensitivity for both gene expression and TCR detection and are based on the recent release of the Version 3 chemistry for its flagship product, Evercode Whole Transcriptome.
Both Evercode BCR and TCR are compatible with fixation, which enables researchers to fix and store samples as they arrive and then later batch samples together in a single experiment. This enables time-courses and higher throughput experiments, while minimizing any potential batch effects between samples.
“Scaling up cell counts and sample numbers are crucial for achieving impactful results in single cell immune profiling,” said Parse Biosciences co-founder and CTO Charlie Roco. “We are excited about the new capabilities researchers will have with these solutions and to provide them with the unmatched scale required to uncover the vast repertoire diversity of the adaptive immune system.”
Parse team members will unveil additional details about Evercode BCR and updates to Evercode TCR at the upcoming American Association of Immunologists (AAI) annual meeting in Chicago on Sunday, May 5 at 10:45 AM in Exhibitor Workshop Theater #1, Hall F1.
